Bladder cancer remains the most common form of urothelial carcinoma, and advances in radiation therapy are reshaping treatment paradigms. Hypofractionation, as part of a trimodal approach, offers a promising strategy for bladder preservation, potentially improving tumor control while minimizing toxicity. Additionally, SBRT has emerged as a valuable tool in the management of oligometastatic urothelial cancer, potentially delaying systemic therapy and prolonging progression-free survival. This webinar explores the latest evidence supporting these approaches and their integration into clinical practice.
